Document Type : Original Article(s)
Authors
1 Department of Clinical Pathology and Laboratory Medicine, Faculty of Medicine, Universitas Andalas, Padang, Indonesia
2 Department of Clinical Pathology, Faculty of Medicine, Universitas Baiturrahmah, Padang, Indonesia
3 Department of Cardiology, Faculty of Medicine, Universitas Andalas, Padang, Indonesia
Abstract
Background: Family with sequence similarity 19, member A5 (FAM19A5) is a secreted protein initially proposed as an adipokine with anti-inflammatory and anti-atherogenic properties. However, recent evidence has challenged this view by demonstrating minimal adipose expression and suggesting that circulating FAM19A5 may instead increase in response to vascular stress and atherogenic progression. To clarify its relevance in obesity-related dyslipidemia, this study examined the association between circulating FAM19A5 and established lipid-based atherogenic indices in a diet-induced obesity model.
Methods: This in vivo correlational study involved 14 male Sprague–Dawley rats (n=7 per group) conducted in Padang, Indonesia, in 2024. Rats were assigned to a control group (American Institute of Nutrition-93 diet) or an obesity group (high-fat and high-fructose diet) for 12 weeks. Serum FAM19A5 levels were measured by ELISA. Derived indices included the LDL/ApoB ratio, Castelli Risk Index I and II, and the HDL-based atherogenic index. Spearman’s correlation analysis was used to assess the correlation (P<0.05), and all analyses were performed using SPSS version 25 (IBM Corp., USA).
Results: FAM19A5 showed a strong positive correlation with the LDL/ApoB ratio (r=0.734, P<0.050), indicating that higher FAM19A5 levels coincide with more atherogenic ApoB-containing lipoprotein patterns. Correlations with Castelli Risk Index I (r=0.127, P>0.05), Castelli Risk Index II (r=0.369, P=0.195), and the HDL-based atherogenic index (r=0.127, P=0.666) were weak and not statistically significant.
Conclusion: Elevated circulating FAM19A5 may serve as a potential biomarker reflecting ApoB-related lipid alterations during obesity progression.
Highlights
Efrida Efrida (Google Scholar)
Keywords
- Henning RJ. Obesity and obesity-induced inflammatory disease contribute to atherosclerosis: a review of the pathophysiology and treatment of obesity. Am J Cardiovasc Dis. 2021;11:504-29. PubMed PMID: 34548951; PubMed Central PMCID: PMC8449192.
- Jebari-Benslaiman S, Galicia-Garcia U, Larrea-Sebal A, Olaetxea JR, Alloza I, Vandenbroeck K, et al. Pathophysiology of Atherosclerosis. Int J Mol Sci. 2022;23. doi: 10.3390/ijms23063346. PubMed PMID: 35328769; PubMed Central PMCID: PMC8954705.
- Kelle BP, Ćesić AK, Čustović S, Ćosović E, Lagumdžija D, Jordamović N, et al. Improvement of a diet-induced model of hyperlipidemia in Wistar rats: Assessment of biochemical parameters, the thickness of the abdominal aorta and liver histology. J King Saud Univ Sci. 2024;36:103068. doi: 10.1016/j.jksus.2023.103068.
- Jung HW, Ra M, Bae HJ, Hong SP. The LDL-C/Apo B predicts coronary atherosclerotic heart disease in non-diabetic patients without high LDL-C. Medicine (Baltimore). 2023;102:e32596. doi: 10.1097/MD.0000000000032596. PubMed PMID: 36607865; PubMed Central PMCID: PMC9829249.
- Efrida E, Rofinda ZD, Lipoeto NI, Bakma I. The correlation of adiponectin, high-sensitivity C-reactive protein, and adiponec-tin/crp ratio to Castelli risk Index-II in cardiovascular disease associated with vitamin-D deficiency in laboratory workers at M. Djamil public hospital, West Sumatra. Med J Nutr Metab. 2024;17:357-67. doi: 10.1177/1973798X241289333.
- De Oliveira-Gomes D, Joshi PH, Peterson ED, Rohatgi A, Khera A, Navar AM. Apolipoprotein B: Bridging the Gap Between Evidence and Clinical Practice. Circulation. 2024;150:62-79. doi: 10.1161/CIRCULATIONAHA.124.068885. PubMed PMID: 38950110; PubMed Central PMCID: PMC11219008.
- Galimberti F, Casula M, Olmastroni E. Apolipoprotein B compared with low-density lipoprotein cholesterol in the atherosclerot-ic cardiovascular diseases risk assessment. Pharmacol Res. 2023;195:106873. doi: 10.1016/j.phrs.2023.106873. PubMed PMID: 37517561.
- Soffer DE, Marston NA, Maki KC, Jacobson TA, Bittner VA, Pena JM, et al. Role of apolipoprotein B in the clinical management of cardiovascular risk in adults: An Expert Clinical Consensus from the National Lipid Association. J Clin Lipidol. 2024;18:e647-e63. doi: 10.1016/j.jacl.2024.08.013. PubMed PMID: 39256087; PubMed Central PMCID: PMC11734832.
- Silbernagel G, Scharnagl H, Saely CH, Reinthaler M, Rief M, Kleber ME, et al. The LDL Apolipoprotein B-to-LDL Cholesterol Ratio: Association with Cardiovascular Mortality and a Biomarker of Small, Dense LDLs. Biomedicines. 2022;10. doi: 10.3390/biomedicines10061302. PubMed PMID: 35740324; PubMed Central PMCID: PMC9220033.
- Kwak H, Cho EH, Cho EB, Lee YN, Shahapal A, Yong HJ, et al. Is FAM19A5 an adipokine? Peripheral FAM19A5 in wild-type, FAM19A5 knockout, and LacZ knockin mice. Mol Cells. 2024;47:100125. doi: 10.1016/j.mocell.2024.100125. PubMed PMID: 39426682; PubMed Central PMCID: PMC11603079.
- Wang Y, Chen D, Zhang Y, Wang P, Zheng C, Zhang S, et al. Novel Adipokine, FAM19A5, Inhibits Neointima Formation After Injury Through Sphingosine-1-Phosphate Receptor 2. Circulation. 2018;138:48-63. doi: 10.1161/CIRCULATIONAHA.117.032398. PubMed PMID: 29453251.
- Ma F, Hao J, Zhao J, Liu DY, Cao HL, Yang B, et al. Circulating FAM19A5 level is associated with the presence and severity of coronary artery disease. Int J Cardiol. 2022;354:50-5. doi: 10.1016/j.ijcard.2022.03.011. PubMed PMID: 35278575.
- Wesolek A, Skoracka K, Skrypnik K, Suliburska J, Bogdanski P, Szulinska M, et al. Assessment of progranulin and FAM19A5 protein blood levels in patients with metabolic syndrome. J Physiol Pharmacol. 2022;73. doi: 10.26402/jpp.2022.1.13. PubMed PMID: 35793765.
- Yari FA, Shabani P, Karami S, Sarmadi N, Poustchi H, Bandegi AR. Circulating levels of FAM19A5 are inversely associated with subclinical atherosclerosis in non-alcoholic fatty liver disease. BMC Endocr Disord. 2021;21:153. doi: 10.1186/s12902-021-00820-8. PubMed PMID: 34344333; PubMed Central PMCID: PMC8335939.
- Zarzour A, Kim HW, Weintraub NL. Understanding Obesity-Related Cardiovascular Disease: It’s All About Balance. Circulation. 2018;138:64-6. doi: 10.1161/CIRCULATIONAHA.118.034454. PubMed PMID: 29967231; PubMed Central PMCID: PMC6053309.
- Gistera A, Ketelhuth DFJ, Malin SG, Hansson GK. Animal Models of Atherosclerosis-Supportive Notes and Tricks of the Trade. Circ Res. 2022;130:1869-87. doi: 10.1161/CIRCRESAHA.122.320263. PubMed PMID: 35679358.
- Ble-Castillo JL, Aparicio-Trapala MA, Juarez-Rojop IE, Torres-Lopez JE, Mendez JD, Aguilar-Mariscal H, et al. Differential effects of high-carbohydrate and high-fat diet composition on metabolic control and insulin resistance in normal rats. Int J Environ Res Public Health. 2012;9:1663-76. doi: 10.3390/ijerph9051663. PubMed PMID: 22754464; PubMed Central PMCID: PMC3386579.
- Marques C, Meireles M, Norberto S, Leite J, Freitas J, Pestana D, et al. High-fat diet-induced obesity Rat model: a comparison between Wistar and Sprague-Dawley Rat. Adipocyte. 2016;5:11-21. doi: 10.1080/21623945.2015.1061723. PubMed PMID: 27144092; PubMed Central PMCID: PMC4836488.
- Sasidharan SR, Joseph JA, Anandakumar S, Venkatesan V, Ariyattu Madhavan CN, Agarwal A. An experimental approach for selecting appropriate rodent diets for research studies on metabolic disorders. Biomed Res Int. 2013;2013:752870. doi: 10.1155/2013/752870. PubMed PMID: 24151620; PubMed Central PMCID: PMC3787574.
- Lee S-I, Kim J-W, Lee Y-K, Yang S-H, Lee I, Suh J-W, et al. Anti-obesity effect of monascus pilosus mycelial extract in high fat diet-induced obese rats. J Appl Biol Chem. 2011;54:197-205. doi: 10.3839/jabc.2011.033.
- National Research Council (US) Committee for the Update of the Guide for the Care and Use of Laboratory Animals. Guide for the care and use of laboratory animals. 8th ed. Washington (DC): National Academies Press; 2011. doi: 10.17226/12910.
- Glavinovic T, Thanassoulis G, de Graaf J, Couture P, Hegele RA, Sniderman AD. Physiological Bases for the Superiority of Apolipoprotein B Over Low-Density Lipoprotein Cholesterol and Non-High-Density Lipoprotein Cholesterol as a Marker of Cardiovascular Risk. J Am Heart Assoc. 2022;11:e025858. doi: 10.1161/JAHA.122.025858. PubMed PMID: 36216435; PubMed Central PMCID: PMC9673669.
- Adelin P, Efrida, Rita RS, Elfi EF. Integration of FAM19A5 Expression, Plasma Atherogenic Index and Coronary Artery Histopathology in Diet-Induced Obese Rats. Pak J Biol Sci. 2026;29:1-9. doi: 10.3923/pjbs.2026.1.9. PubMed PMID: 41622955.
)